Asoglu, VeysiUmit, Elif G.Demir, Muzaffer2024-06-122024-06-1220191752-03631752-0371https://doi.org/10.2217/bmm-2018-0236https://hdl.handle.net/20.500.14551/21918Background: Immune thrombocytopenia (ITP) is an acquired disease characterized by various pathogenetic mechanisms. We aimed to evaluate the value of TRAF6 as a biomarker of pathogenesis in ITP. Methods:85 newly diagnosed ITP patients and 85 controls were included. Results: In the patient group, mean TRAF6 level was 2348pg/ml and in the control group, TRAF6 level was 25.57pg/ml. In corticosteroid-responding patients, TRAF6 levels were lower than nonresponding patients. Discussion: TRAF6 levels were observed to be higher than healthy controls, which suggest a solid relation with ITP pathogenesis. The observation that in patients who present with high TRAF6 levels, there was a significant corticosteroid refractoriness and responsiveness.en10.2217/bmm-2018-0236info:eu-repo/semantics/closedAccessImmune ThrombocytopeniaImmunityTRAF6PurpuraPathophysiologyAutoantibodiesArticle1312731Q3WOS:0004583317000042-s2.0-8506003573430556735Q3